<?xml version='1.0' encoding='utf-8'?>
<document id="23033255"><sentence text="Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors." /><sentence text="Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism" /><sentence text=" It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems" /><sentence text=" The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in the intestine suggest its potentially indispensable role in first-pass intestinal metabolism and involvement in drug-drug interaction" /><sentence text=" To fully characterize its role in drug metabolism, selective and potent inhibitors of CYP2J2 are necessary tools" /><sentence text=" In the current study, 69 known drugs were screened for the inhibition of CYP2J2, and we discovered a number of marketed drugs as potent and selective CYP2J2 inhibitors" /><sentence text=" In particular, telmisartan and flunarizine have CYP2J2 inhibition IC(50) values of 0"><entity charOffset="16-27" id="DDI-PubMed.23033255.s7.e0" text="telmisartan" /><entity charOffset="32-43" id="DDI-PubMed.23033255.s7.e1" text="flunarizine" /><pair ddi="false" e1="DDI-PubMed.23033255.s7.e0" e2="DDI-PubMed.23033255.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23033255.s7.e0" e2="DDI-PubMed.23033255.s7.e1" /></sentence><sentence text="42 μM and 0" /><sentence text="94 μM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no time-dependent inhibition toward this CYP" /><sentence text=" The results of enzyme kinetics studies, supported by molecular modeling, have also elucidated that telmisartan is a mixed-type inhibitor, and flunarizine competitively inhibits CYP2J2"><entity charOffset="100-111" id="DDI-PubMed.23033255.s10.e0" text="telmisartan" /><entity charOffset="143-154" id="DDI-PubMed.23033255.s10.e1" text="flunarizine" /><pair ddi="false" e1="DDI-PubMed.23033255.s10.e0" e2="DDI-PubMed.23033255.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23033255.s10.e0" e2="DDI-PubMed.23033255.s10.e1" /></sentence><sentence text=" The K(i) for telmisartan is 0"><entity charOffset="14-25" id="DDI-PubMed.23033255.s11.e0" text="telmisartan" /></sentence><sentence text="19 μM, with an α value, an indicator of the type of inhibition mechanism, of 2" /><sentence text="80, and flunarizine has a K(i) value of 0"><entity charOffset="8-19" id="DDI-PubMed.23033255.s13.e0" text="flunarizine" /></sentence><sentence text="13 μM" /><sentence text=" These newly discovered CYP2J2 inhibitors can be potentially used as a tool to study CYP2J2 in drug metabolism and interaction in a clinical setting" /><sentence text="" /></document>